---
id: 166
title: JC Polyomavirus (JCPyV) - Progressive Multifocal Leukoencephalopathy
category: organisms
subcategory: polyomaviruses
tags: [JC-virus, PML, leukoencephalopathy, natalizumab, HIV, demyelination]
difficulty: medium
---

## Question

How is PML diagnosed and managed? Use the **"Demyelination in Immunocompromised (HIV, Natalizumab) → CSF JC PCR + MRI → Restore Immunity"** framework.

## Answer

### **JC Polyomavirus (JCPyV) Overview:**

**Epidemiology:**
- **Primary infection:** Childhood (50-80% seropositive by adulthood)
- **Latency:** Kidneys, bone marrow, CNS
- **Reactivation:** Severe immunosuppression

### **Progressive Multifocal Leukoencephalopathy (PML):**

**Pathophysiology:**
- **JCPyV reactivation** → infects oligodendrocytes (myelin-producing cells) → **demyelination**

**Risk Factors:**
- **HIV/AIDS** (CD4 <200, especially <50) - most common
- **Immunosuppressive drugs:** Natalizumab (MS treatment), rituximab, fingolimod
- **Hematologic malignancies:** Lymphoma, CLL, transplant
- **Other immunosuppression:** Chronic steroids, transplant

### **Clinical Presentation:**

**Neurologic Deficits (Subacute, Progressive):**
- **Cognitive impairment:** Confusion, memory loss, personality changes
- **Motor deficits:** Weakness, ataxia, gait disturbance
- **Visual deficits:** Hemianopsia, cortical blindness (occipital involvement)
- **Speech deficits:** Aphasia, dysarthria
- **NO fever** (non-inflammatory)

**Progression:**
- **Weeks to months** (subacute, relentlessly progressive)
- **Fatal without immune recovery** (median survival 3-6 months untreated)

### **Diagnosis:**

**MRI Brain (Gold Standard Imaging):**
- **White matter lesions** (multifocal, asymmetric)
- **T2/FLAIR:** Hyperintense lesions (demyelination)
- **Location:** Subcortical white matter (spares cortex), U-fibers (subcortical arcuate fibers)
- **NO mass effect, NO enhancement** (usually) - distinguishes from toxoplasmosis, lymphoma
- **Progressive enlargement** over time

**CSF Analysis:**
- **JC virus PCR:** **Gold standard for diagnosis** (sensitivity 70-90%, specificity >95%)
- **CSF profile:** Usually normal (mild lymphocytic pleocytosis, mildly ↑protein)

**Brain Biopsy:**
- **Definitive** (if CSF PCR negative but high clinical suspicion)
- **Histology:** Demyelination, bizarre astrocytes, enlarged oligodendrocyte nuclei with viral inclusions
- **Rarely needed** (CSF PCR + MRI usually diagnostic)

### **Treatment:**

**Primary Strategy: Restore Immune Function:**

**HIV-Associated PML:**
- **Start/optimize ART** (antiretroviral therapy)
- **Immune reconstitution** = only effective treatment
- **Outcomes:** 50% 1-year survival with ART (vs. near 100% mortality without)

**Natalizumab-Associated PML:**
- **Discontinue natalizumab immediately**
- **Plasma exchange (PLEX):** 3-5 sessions over 1-2 weeks (removes natalizumab, accelerates immune recovery)
- **Risk:** **IRIS** (immune reconstitution inflammatory syndrome) in 60-80%

**Other Immunosuppression:**
- **Reduce/stop immunosuppressive drugs** if feasible

**NO Effective Antiviral:**
- **No FDA-approved antiviral** for JC virus
- **Cidofovir, cytarabine, mefloquine, mirtazapine** - tried historically, **NO proven efficacy**

**Immune Reconstitution Inflammatory Syndrome (IRIS):**

**Presentation:**
- **Worsening neurologic symptoms** after starting ART (HIV) or stopping natalizumab
- **MRI:** Contrast enhancement, edema, mass effect (inflammatory response)
- **Timing:** Weeks after immune recovery initiated

**Management:**
- **Corticosteroids:** Methylprednisolone 1g IV daily × 3-5 days → prednisone taper (reduces inflammation)
- **Continue ART** (do NOT stop, need immune recovery)
- **Supportive care**

### **Prognosis:**

**HIV-Associated:**
- **50% 1-year survival** with ART
- **Near 100% mortality** without ART

**Natalizumab-Associated:**
- **Better outcomes** (if diagnosed early, PLEX performed)
- **IRIS common** (60-80%)

**Predictors of Poor Outcome:**
- **Severe baseline deficits**
- **Large lesion burden** (MRI)
- **Low CD4 count** (HIV)
- **Delayed diagnosis**

## Key Points

### **PML = Demyelination in Immunocompromised:**
- **Subacute, progressive neurologic deficits** (cognitive, motor, visual, speech)
- **NO fever** (non-inflammatory)
- **Fatal without immune recovery**

### **MRI Findings:**
- **Multifocal white matter lesions** (asymmetric)
- **Subcortical, U-fiber involvement**
- **NO mass effect, NO enhancement** (distinguishes from toxo, lymphoma)

### **CSF JC PCR = Diagnostic:**
- **Sensitivity 70-90%, specificity >95%**
- **Negative PCR does NOT exclude** (repeat if high suspicion, consider biopsy)

### **Restore Immunity = ONLY Treatment:**
- **HIV:** Start/optimize ART
- **Natalizumab:** Stop drug + PLEX
- **NO effective antiviral**

### **IRIS Common:**
- **Worsening symptoms** after immune recovery (ART, stopping natalizumab)
- **MRI:** Enhancement, edema (inflammatory response)
- **Treat with corticosteroids** (methylprednisolone), continue ART

### **Natalizumab Risk:**
- **MS treatment** (anti-VLA-4 antibody)
- **PML risk:** 1-5 per 1000 (higher if JC antibody+, prior immunosuppression, >2 years treatment)
- **Monitor:** MRI every 3-6 months if high-risk

### **Clinical Pearls:**
- **Subacute neurologic deficits in immunocompromised** (HIV, natalizumab) → suspect PML
- **MRI:** Multifocal white matter lesions, NO enhancement → **CSF JC PCR**
- **Treatment:** Restore immunity (ART for HIV, stop natalizumab + PLEX)
- **NO effective antiviral**
- **IRIS common** after immune recovery → treat with steroids, continue immune restoration

## Sources

- [AAN: PML Guidelines 2024]
- [CID: PML in HIV and Non-HIV 2024]

## Media

N/A
